ANGIODYNAMICS INC (ANGO)
US03475V1017 - Common Stock
Tuesday 4/9 Insider Buying Report: ZUMZ, ANGO
ANGO Stock Earnings: AngioDynamics Misses EPS, Misses Revenue for Q3 2024
ANGO stock results show that AngioDynamics missed analyst estimates for earnings per share and missed on revenue for the third quarter of 2024.
ANGO Stock Earnings: AngioDynamics Misses EPS, Misses Revenue for Q3 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips AngioDynamics (NASDAQ:ANGO) just reported results for the third quarter of 2024...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're diving into the biggest pre-market stock movers that traders are going to want to keep an eye on for Thursday morning!
AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE
AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.
AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024
AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference
Hidden Gems: 7 Oversold Stocks Ready for a Major Rebound
While red ink signals danger, for these oversold stocks ready for rebound, they could imply upside opportunities.
AngioDynamics divests PICC, Midline product portfolio (NASDAQ:ANGO)
AngioDynamics (ANGO) has sold its PICC and Midline product portfolio to Spectrum Vascular for $45M in cash as part of a restructuring effort. The portfolio, whi
AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million
AngioDynamics gets FDA clearance for Auryon XL catheter (NASDAQ:ANGO)
AngioDynamics (ANGO) has received FDA clearance for its Auryon XL radial access catheter for the treatment of peripheral artery disease. Read more here.
AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease
Commit To Purchase AngioDynamics At $5, Earn 9.6% Annualized Using Options
Why AngioDynamics Stock Got Destroyed Today
The medical technology company is a perennial underperformer, but its latest quarterly report was worse than expected.
ANGO Stock Earnings: AngioDynamics Beats EPS, Misses Revenue for Q2 2024
ANGO stock results show that AngioDynamics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
ANGO Stock Earnings: AngioDynamics Beats EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips AngioDynamics (NASDAQ:ANGO) just reported results for the second quarter of 202...
AngioDynamics Enters Oversold Territory (ANGO)
AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance
AngioDynamics to Present at the J.P. Morgan Healthcare Conference
AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024
AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism
(NASDAQ:ANGO)
AngioDynamics (ANGO) reports Q1 financial results with Non-GAAP EPS of -$0.12 and revenue of $78.7M.